The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

It’s so special to be playing for a purpose, the purpose being this incredible mission,” Eddie Vedder tells TODAY.com.

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...

A Mayo woman who suffers from a rare, genetic skin disease will abseil from the roof of Croke Park to fundraise for a charity ...

The FDA has approved Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a Cleveland-based biotech company, announced Monday, May 12, that it has entered an ...

The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review ...